Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 2
2002 3
2003 3
2004 8
2005 3
2006 5
2007 5
2008 6
2009 11
2010 11
2011 18
2012 15
2013 12
2014 22
2015 12
2016 17
2017 15
2018 17
2019 29
2020 29
2021 32
2022 15
2023 20
2024 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for di giambenedetto s
Search for Di Gaimbenedetto S instead (2 results)
Pillars of long-term antiretroviral therapy success.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D'Arminio Monforte A, D'Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F. Taramasso L, et al. Among authors: di giambenedetto s. Pharmacol Res. 2023 Oct;196:106898. doi: 10.1016/j.phrs.2023.106898. Epub 2023 Aug 28. Pharmacol Res. 2023. PMID: 37648103 Free article. Review.
Sexually transmitted infections in people with multidrug-resistant HIV.
Clemente T, Lolatto R, Papaioannu Borjesson R, Fabbiani M, Manzillo E, Fronti E, Di Giambenedetto S, Gagliardini R, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Among authors: di giambenedetto s. AIDS. 2023 Dec 1;37(15):2425-2430. doi: 10.1097/QAD.0000000000003690. Epub 2023 Nov 16. AIDS. 2023. PMID: 37965740
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen.
Iannone V, Passerotto RA, Lamanna F, Steiner RJ, Lombardi F, Salvo PF, Dusina A, Farinacci D, Borghetti A, Di Giambenedetto S, Ciccullo A. Iannone V, et al. Among authors: di giambenedetto s. Viruses. 2023 Apr 25;15(5):1046. doi: 10.3390/v15051046. Viruses. 2023. PMID: 37243133 Free PMC article.
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
Kabra M, Barber TJ, Allavena C, Marcelin AG, Di Giambenedetto S, Pasquau J, Gianotti N, Llibre JM, Rial-Crestelo D, De Miguel-Buckley R, Blick G, Turner M, Harrison C, Wynne T, Verdier G, Parry CM, Jones B, Okoli C, Donovan C, Priest J, Letang E. Kabra M, et al. Among authors: di giambenedetto s. Open Forum Infect Dis. 2023 Oct 27;10(11):ofad526. doi: 10.1093/ofid/ofad526. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38033982 Free PMC article.
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F, Giacomelli A, Borghi V, Ciccullo A, Taramasso L, Madeddu G, D'Ettorre G, Giacometti A, Ducci F, De Vito A, Pincino R, Di Giambenedetto S, Mussini C, Antinori S, Sterrantino G. Lagi F, et al. Among authors: di giambenedetto s. J Med Virol. 2023 Oct;95(10):e29149. doi: 10.1002/jmv.29149. J Med Virol. 2023. PMID: 37805832
Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Ciccullo A, et al. Among authors: di giambenedetto s. Expert Rev Anti Infect Ther. 2020 Apr;18(4):279-292. doi: 10.1080/14787210.2020.1729742. Epub 2020 Feb 18. Expert Rev Anti Infect Ther. 2020. PMID: 32067525 Review.
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S. Ciccullo A, et al. Among authors: di giambenedetto s. Int J Antimicrob Agents. 2024 Jan;63(1):107040. doi: 10.1016/j.ijantimicag.2023.107040. Epub 2023 Nov 20. Int J Antimicrob Agents. 2024. PMID: 37981074
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Fabbiani M, Masini M, Rossetti B, Ciccullo A, Borghi V, Lagi F, Capetti A, Colafigli M, Panza F, Baldin G, Mussini C, Sterrantino G, Farinacci D, Montagnani F, Tumbarello M, Di Giambenedetto S. Fabbiani M, et al. Among authors: di giambenedetto s. Viruses. 2023 May 8;15(5):1123. doi: 10.3390/v15051123. Viruses. 2023. PMID: 37243208 Free PMC article.
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
296 results